Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way.
Accumulating evidence has proven the safety and feasibility of radical prostatectomy and
local or metastasis-directed radiotherapy for oligometastatic patients. The aim of this trial
is to compare the safety and feasibility outcomes of metastasis-directed neoadjuvant
radiotherapy (naRT) and neoadjuvant androgen deprivation therapy (naADT) followed by
robotic-assisted radical prostatectomy (RARP) to ADT combined with abiraterone for treating
OMPC.